Buch, Englisch, 488 Seiten, Format (B × H): 216 mm x 276 mm, Gewicht: 1340 g
Buch, Englisch, 488 Seiten, Format (B × H): 216 mm x 276 mm, Gewicht: 1340 g
ISBN: 978-0-12-404748-8
Verlag: William Andrew Publishing
This book is also focused on the challenges of diagnostic interpretation of NGS results in a clinical setting. Its final sections are devoted to the emerging regulatory issues that will govern clinical use of NGS, and reimbursement paradigms that will affect the way in which laboratory professionals get paid for the testing.
Zielgruppe
<p>Clinical Genomicists, Molecular Pathologists, molecular Geneticists, clinical Cytogeneticists, Clinical Geneticists, Primary Care Physicians (including Oncologists, Pediatricians, Neurologists, Cardiologists, and Neonatologists) and Genetic Counselors seeking to use or interpret Next Gen Sequencing in the diagnosis, prognosis, and management of inherited and somatic disorders in the era of precision medicine.</p>
Autoren/Hrsg.
Fachgebiete
- Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Vorklinische Medizin: Grundlagenfächer Humangenetik
- Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Vorklinische Medizin: Grundlagenfächer Molekulare Medizin, Zellbiologie
- Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Medizinische Fachgebiete Pathologie, Cytopathologie, Histopathologie
Weitere Infos & Material
Section 1: Methods
- Overview of technical aspects and chemistries of NGS: Dr Robi Mitra, Washington University School of Medicine.
- Non-selective methods (genome-wide): Dr Mark Bogoski, Harvard Medical School
- Capture based methods (exome, panels) Dr Birgit Funke, Harvard Medical School
- Amplification based methods (panels): Dr Madhuri Hegde, Emory Medical School
- Emerging technologies (Nanopore and others); impact on cost and turnaround time: Dr Elaine Mardis, Washington University School of Medicine.
Section 2: Bioinformatics
- Base calling and alignment; quality metrics; depth of coverage: Dr Carl Volkerding, University of Utah, ARUP labs
- Single nucleotide variants (SNVs): Dr David Spencer, Washington University School of Medicine
- Insertions and deletions (Indels): Drs Eric Duncavage and Haley Abel, Washington University School of Medicine
- Large structural alterations (big deletions, translocations, and so on): Dr Charles Mullighan, St Jude's Cancer Institute
- Copy number variants (CNVs): Dr Mary-Claire King, University of Washington
Section 3: Interpretation
- Reference data bases for disease associations: Dr Heidi Rehm, Harvard Medical School
- Reporting of results; level of evidence for associations; classes of associations: Dr Shashikant Kulkarni, Washington University School of Medicine
- Constitutional diseases (with individual chapters on hypertrophic cardiomyopathy, congenital deafness, blindness, cancer syndromes, and so on): Dr David Bick and Dr David Dimmock, Medical College of Wisconsin
- Cancer (with individual chapters on leukemia, lymphoma, lung cancer, colon cancer, and so on): Dr John Pfeifer, Washington University School of Medicine
Section 4: Regulatory Issues
- Assay validation: Dr Ira Lublin, CDC and Dr Elizabeth Mansfield FDA
- QA/QC/PT issues: Dr Elaine Lyon, University of Utah, ARUP labs
- Consent and privacy issues: Dr James DuBois, Albert Gnaegi Center for Health Care Ethics
Section 5: Reimbursement
- Billing: Andrew Drury and Kris Rickoff, Washington University School of Medicine